Galderma Competitive Intelligence & Landscape

Galderma (galderma.com) is a pure-play dermatology company committed to advancing dermatology for every skin story. Founded in 1981, the company has over 40 years of heritage in science-based innovation, focusing exclusively on the human body's largest organ: the skin [galderma.com/about-us].

Galderma operates with an Integrated Dermatology Strategy, offering a comprehensive portfolio of cutting-edge, premium brands.

Galderma's core offerings span three distinct, consumer-focused sub-segments of dermatology: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology [galderma.com, galderma.com/glance]. The company provides a synergistic portfolio of flagship brands, such as ALASTIN Skincare®, known for supporting skin appearance after aesthetic procedures and restoring daily skin health [galderma.com/our-brands]. Their innovative product range is supported by science-based differentiation and premium positioning.

The target market for Galderma includes individual consumers and patients with diverse skin needs, as well as healthcare professionals and customers [galderma.com/careers]. The company embraces the uniqueness of everyone's skin story, striving to offer solutions that fit individual needs across the full spectrum of dermatology [galderma.com]. Their mission is to make a positive impact on people's lives globally by advancing dermatology for every skin story [galderma.com/sites/default/files/2025-03/galderma_annual_report_2024.pdf].

While Galderma maintains a global presence, specific contact information for market offices, including the United States, is available through their contact us page [galderma.com/contact-us]. The company's governance is overseen by a Board of Directors, with members elected annually [galderma.com/governance].

Galderma's commitment to innovation, a broad portfolio, and a clear purpose underpins its ambition to maintain category leadership in dermatology [galderma.com/careers].

Galderma (galderma.com) offers a comprehensive portfolio of premium brands across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology to address diverse skin needs [galderma.com]. Their product range includes well-known brands such as ALASTIN Skincare® for rejuvenation and daily skin health, and Benzac and Cetaphil which offer solutions for acne and general skincare, respectively [galderma.com/our-brands]. In Therapeutic Dermatology, Galderma provides prescription treatments for conditions like acne, rosacea, and non-melanoma skin cancer, demonstrating a commitment to addressing unmet medical needs [galderma.com/therapeutic-dermatology].

Galderma emphasizes a premium positioning for its brands, driven by science-based product differentiation [galderma.com/our-brands]. While specific pricing plans for consumers are not directly listed on their global website, they make information about Average Wholesale Prices (AWP) for certain drugs available to prescribers in regions like Vermont [galderma.com/us/sites/default/files/2024-04/VT_Oracle%20Letter_LV2024.pdf]. It is noted that the price paid by consumers may vary from these AWPs, which are established by third-party publishers [galderma.com/us/sites/default/files/2024-04/VT_Oracle%20Letter_LV2024.pdf]. For detailed product information, program offerings, and authorized retailers, consumers are directed to visit individual brand websites [galderma.com/us/contact-us].

Galderma's strategy includes making their brands accessible to as many patients and consumers as possible, which is a core part of their purpose [galderma.com/sites/default/files/2023-10/20231010_Market%20Access%20at%20Galderma.pdf]. They also explore ways to expand access to their brands for underserved patient populations through Access to Medicine Programs [galderma.com/sites/default/files/2023-10/20231010_Market%20Access%20at%20Galderma.pdf]. There is no information available on the Galderma website regarding free vs. paid features, pricing tiers, or recent pricing changes directly applicable to consumers.

Galderma (galderma.com) actively seeks to expand its workforce, emphasizing scientific innovation and a commitment to advancing dermatology. The company maintains a dedicated careers section on its global and regional websites, such as galderma.com/careers and galderma.com/us/careers, where interested candidates can explore current job opportunities worldwide.

Prospective employees can search, find, and apply to positions globally through the company's job search portal galderma.com/job-search.

Galderma also offers a job agent feature, allowing individuals to create alerts for new opportunities that match their preferences, ensuring they stay updated with the latest roles as they become available galderma.com/agent.

The company’s strategy for talent acquisition signals a strong focus on growth and innovation, seeking “bold and sophisticated talent with the capacity to innovate, collaborate and execute across teams and geographies.” This approach supports their ambition to lead in dermatology, as highlighted on their strategy page galderma.com/our-strategy. While specific layoff information is not available from the provided sources, the emphasis on a thriving workplace and continuous development through initiatives like the 2023 Development Month underscores a positive internal culture for existing employees galderma.com/our-employees.

Galderma encourages sharing of job opportunities via social media galderma.com/job-share, indicating a proactive and modern approach to recruitment. Their continuous recruitment for diverse skills and passionate individuals across the globe reflects a sustained effort to strengthen their position in the dermatology industry, focusing on areas like Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology, as mentioned on their homepage.

Galderma (galderma.com) has demonstrated robust financial performance, achieving record net sales of 5.207 billion USD in 2025, marking a 17.7% year-on-year growth on a constant currency basis, and surpassing 5 billion USD for the first time [https://www.galderma.com/news/galderma-delivers-record-2025-results]. The company's Core EBITDA also reached 1.211 billion USD in 2025, an 18.9% increase at constant currency [https://investors.galderma.com/news-releases/news-release-details/galderma-delivers-record-2025-results-net-sales-5207-billion-usd]. This strong performance was consistent with previous years, as Galderma also reported record net sales of 4.410 billion USD in 2024, an increase of 9.3% year-on-year at constant currency, with Core EBITDA of 1.031 billion USD [https://www.galderma.com/news/galderma.com/news/2024-annual-results].

Galderma entered 2025 with significant momentum following its landmark Initial Public Offering (IPO) on the SIX Swiss Exchange in 2024 [https://www.galderma.com/annual-report-2025]. This IPO was notably the largest in Switzerland since 2017 and one of the largest healthcare IPOs ever, positioning Galderma as a publicly-listed company (SIX:GALD) and marking a crucial turning point in its growth trajectory [https://www.galderma.com/annual-report-2024]. The company continues to provide quarterly trading updates and financial reports on its investor relations page [https://investors.galderma.com/financial-reports/].

In the first quarter of 2026, Galderma reported a strong start to the year with net sales of 1.473 billion USD. This growth was primarily driven by volume, complemented by positive price and mix effects, reinforcing the company's integrated dermatology strategy [https://www.galderma.com/news/galderma-Q12026-performance]. This consistent financial strength underscores Galderma's position as a pure-play dermatology category leader, continually advancing its portfolio across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology [https://galderma.com/].

Galderma (galderma.com) actively participates in and hosts numerous events, showcasing its leadership in dermatology and aesthetic innovations. In 2026, the company will present the latest updates on its innovative cross-dermatology portfolio at the American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, from March 27-31, where it will also host a product theater focusing on atopic dermatitis and prurigo [galderma.com/news/aad-2026-galderma-scientific-presentations].

Galderma is a prominent presence at major international congresses. At the IMCAS 2026 World Congress in Paris, France, from January 29-31, 2026, Galderma will present ten posters on its broad aesthetic portfolio and host two symposia, a live anatomy workshop, and multiple educational events, showcasing its leadership in community education [galderma.com/news/imcas-2026-galderma-showcases-latest-scientific-advances]. Similarly, at the AMWC 2026 (Aesthetic & Anti-Aging Medicine World Congress), Galderma will present nine posters highlighting the regenerative benefits of Sculptra® and the efficacy of Restylane®, demonstrating a comprehensive portfolio and future-focused aesthetic strategies [galderma.com/news/amwc-2026-galderma]. The company also participated in AMWC Dubai, demonstrating leadership through scientific innovations and community education in injectable aesthetics [galderma.com/news/amwc-dubai-galderma-demonstrates-injectable-aesthetics-leadership].

Further demonstrating its commitment to scientific advancement, Galderma will present data from its Injectable Aesthetics portfolio at the TOXINS 2026 International Conference in Madrid, Spain, from January 14-17. Here, it will also host a Relfydess® Masterclass, discussing clinical data and the science behind PEARL™ Technology [galderma.com/news/toxins-2026-galdermas-scientific-presentations]. For 2025, Galderma plans to host a symposium at AMWC 2025 exploring aesthetic treatments for facial changes linked to medication-driven weight loss and another dedicated to Restylane® Kysse™ for ideal lips. The company will also present 11 e-posters, host multiple Masterclass and Meet-the-Expert sessions, and feature an experiential lounge and interactive booth [galderma.com/news/amwc-2025-galderma-pushes-innovation-frontier]. Additionally, Galderma will present data from its Therapeutic Dermatology portfolio at the XIV International Congress of Dermatology (ICD) in Rome, Italy, from June 18-21, 2025, covering updates in acne, non-melanoma skin cancer, and prurigo nodularis [galderma.com/news/international-congress-dermatology-2025-galdermas-scientific-presentations].

Beyond scientific congresses, Galderma engages with the financial community. Upcoming investor events include the JP Morgan Stockholm Access Day on August 26, the UBS Best of Switzerland Conference on September 24, a Q3 2026 trading update on October 22, and the BofA EMEA conference on November 18 [investors.galderma.com/events-presentations/].